Mimotopes and Genzyme Pharmaceuticals to collaborate
Friday, 27 January, 2006
PharmAust's (ASX:PAA) subsidiary Mimotopes and US-based Genzyme Corporation have signed a strategic alliance agreement to provide a total suite of peptide products and services to both companies' customer bases.
The exclusive and global agreement commences on February 1, 2006.
Mimotopes will supply customers with research grade peptides and related services up to the point of lead candidate identification in pre-clinical applications.
Genzyme Pharmaceuticals, a business unit of Genzyme Corporation that develops and manufactures peptide and lipid products, will supply customers with identified lead candidate peptides for pre-clinical applications through to clinical and therapeutic grade peptides and related services.
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
